Development of pegylated liposomal vinorelbine formulation using "post-insertion" technology.

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery Systems
• Nanotechnology

Background:

• Prolonged exposure to vinorelbine enhances its antineoplastic effects.
• Continuous infusion improves response rates but is clinically challenging.
• Pegylated liposomal formulations aim to mimic continuous infusion for better efficacy.

Purpose of the Study:

• To develop a stable pegylated liposomal vinorelbine formulation resistant to premature drug release.
• To overcome challenges associated with using DSPE-PEG in liposome preparation.
• To evaluate the therapeutic efficacy of the novel formulation.

Main Methods:

• Utilized "post-insertion" technology to incorporate DSPE-PEG into pre-formed vinorelbine-containing liposomes.
• Employed High-Performance Liquid Chromatography (HPLC) to confirm DSPE-PEG insertion and assess drug release.
• Evaluated pharmacokinetic profiles in mice and antineoplastic effects in L1210, S-180, and RM-1 tumor models.

Main Results:

• "Post-insertion" successfully integrated DSPE-PEG into liposomes without inducing vinorelbine release.
• Formulations prepared via "post-insertion" exhibited superior drug retention compared to "co-dissolving" methods.
• A pegylated liposomal vinorelbine formulation with 0.5% PEG grafting density showed significant antineoplastic activity in vivo.

Conclusions:

• "Post-insertion" technology effectively prevents detrimental interactions between DSPE-PEG and vinorelbine.
• This method facilitates the development of stable and therapeutically effective pegylated liposomal vinorelbine formulations.
• The developed formulation presents a promising alternative for cancer therapy.